Agendia ®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive ...

Agendia ®, Inc., announced today that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 31 st – June 4 ...

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia ®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early ...

Agendia ®, Inc., announced today that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO), taking place May 31 st ...

Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO FLEX data underscores MammaPrint® utility in accurately predicting ...

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia ®, Inc., announced today that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology ...

Agendia ®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two ...